RAPT Therapeutics (RAPT) Competitors $0.83 +0.02 (+2.18%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RAPT vs. ALGS, EDIT, IVA, ABOS, LPTX, MGX, TARA, XFOR, JMAC, and INMBShould you be buying RAPT Therapeutics stock or one of its competitors? The main competitors of RAPT Therapeutics include Aligos Therapeutics (ALGS), Editas Medicine (EDIT), Inventiva (IVA), Acumen Pharmaceuticals (ABOS), Leap Therapeutics (LPTX), Metagenomi (MGX), Protara Therapeutics (TARA), X4 Pharmaceuticals (XFOR), Maxpro Capital Acquisition (JMAC), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry. RAPT Therapeutics vs. Aligos Therapeutics Editas Medicine Inventiva Acumen Pharmaceuticals Leap Therapeutics Metagenomi Protara Therapeutics X4 Pharmaceuticals Maxpro Capital Acquisition INmune Bio RAPT Therapeutics (NASDAQ:RAPT) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings. Does the MarketBeat Community favor RAPT or ALGS? RAPT Therapeutics received 62 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. However, 65.85% of users gave Aligos Therapeutics an outperform vote while only 62.68% of users gave RAPT Therapeutics an outperform vote. CompanyUnderperformOutperformRAPT TherapeuticsOutperform Votes8962.68% Underperform Votes5337.32% Aligos TherapeuticsOutperform Votes2765.85% Underperform Votes1434.15% Is RAPT or ALGS more profitable? RAPT Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,283.19%. RAPT Therapeutics' return on equity of -89.10% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets RAPT TherapeuticsN/A -89.10% -76.13% Aligos Therapeutics -1,283.19%-114.34%-64.58% Do analysts recommend RAPT or ALGS? RAPT Therapeutics currently has a consensus target price of $9.50, suggesting a potential upside of 1,050.96%. Aligos Therapeutics has a consensus target price of $75.00, suggesting a potential upside of 88.25%. Given RAPT Therapeutics' higher probable upside, equities research analysts plainly believe RAPT Therapeutics is more favorable than Aligos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RAPT Therapeutics 1 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.08Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in RAPT or ALGS? 99.1% of RAPT Therapeutics shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 6.6% of RAPT Therapeutics shares are owned by insiders. Comparatively, 8.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, RAPT or ALGS? RAPT Therapeutics has a beta of 0.07, indicating that its stock price is 93% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.73, indicating that its stock price is 173% more volatile than the S&P 500. Which has preferable valuation and earnings, RAPT or ALGS? Aligos Therapeutics has higher revenue and earnings than RAPT Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRAPT Therapeutics$1.53M18.86-$116.80M-$2.77-0.30Aligos Therapeutics$6.00M23.84-$87.68M-$13.32-2.99 Does the media favor RAPT or ALGS? In the previous week, Aligos Therapeutics had 3 more articles in the media than RAPT Therapeutics. MarketBeat recorded 3 mentions for Aligos Therapeutics and 0 mentions for RAPT Therapeutics. Aligos Therapeutics' average media sentiment score of 0.57 beat RAPT Therapeutics' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment RAPT Therapeutics Neutral Aligos Therapeutics Positive SummaryAligos Therapeutics beats RAPT Therapeutics on 10 of the 18 factors compared between the two stocks. Ad WealthPress70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.>> You can grab your FREE, laminated copies right here << Get RAPT Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRAPT TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.24M$6.57B$5.13B$9.07BDividend YieldN/A2.99%5.08%4.23%P/E Ratio-0.3010.4289.5817.17Price / Sales18.86195.801,116.12116.95Price / CashN/A57.1642.8237.86Price / Book0.195.094.774.78Net Income-$116.80M$151.83M$120.15M$225.60M7 Day Performance-9.30%-2.13%-1.92%-1.23%1 Month Performance-20.25%-3.10%11.47%3.36%1 Year Performance-96.31%11.54%30.54%16.60% RAPT Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRAPT Therapeutics4.5209 of 5 stars$0.83+2.2%$9.50+1,051.0%-96.1%$28.24M$1.53M-0.3080ALGSAligos Therapeutics3.9844 of 5 stars$35.40+3.9%$75.00+111.9%+161.2%$127.02M$6.00M-2.5690News CoverageGap DownHigh Trading VolumeEDITEditas Medicine4.3843 of 5 stars$1.53+5.9%$7.00+359.0%-87.2%$125.89M$78.12M-0.62230IVAInventiva3.1205 of 5 stars$2.32-5.3%$13.25+471.1%-45.3%$121.75M$15.62M0.00100ABOSAcumen Pharmaceuticals3.1582 of 5 stars$1.97-3.0%$9.33+373.8%-39.9%$118.36MN/A-1.4751Short Interest ↓News CoverageLPTXLeap Therapeutics1.2939 of 5 stars$3.06+3.7%$7.50+145.1%-1.0%$117.26M$1.50M-1.5340Positive NewsGap DownMGXMetagenomi2.1309 of 5 stars$3.10-4.3%$16.67+437.6%N/A$116.01M$55.08M0.00236High Trading VolumeTARAProtara Therapeutics2.3557 of 5 stars$5.61-6.2%$22.67+304.0%+196.2%$115.73MN/A-2.1230XFORX4 Pharmaceuticals4.3341 of 5 stars$0.66-1.1%$3.50+428.2%-16.4%$113.01MN/A-8.2280Gap DownJMACMaxpro Capital AcquisitionN/A$8.34+7.8%N/A+837.6%$112.00MN/A0.002,021Gap DownINMBINmune Bio1.4805 of 5 stars$5.02+5.7%$20.00+298.4%-55.7%$111.30M$42,000.00-2.1810 Related Companies and Tools Related Companies Aligos Therapeutics Competitors Editas Medicine Competitors Inventiva Competitors Acumen Pharmaceuticals Competitors Leap Therapeutics Competitors Metagenomi Competitors Protara Therapeutics Competitors X4 Pharmaceuticals Competitors Maxpro Capital Acquisition Competitors INmune Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RAPT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding RAPT Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share RAPT Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RAPT Stock Alerts